When should I take simvastatin tablets

There is no strict regulation on the use time of simvastatin tablets, but it is best to take it after a meal, so that your condition can improve faster and avoid some adverse effects on your gastrointestinal tract. This drug is mainly used to treat some cardiovascular diseases, such as hyperlipidemia, hypertension and coronary heart disease, which are all chronic diseases.

The safety and efficacy of simvastatin in patients aged 10 to 17 years with heterozygous familial hypercholesterolemia have been evaluated in a controlled trial conducted in adolescent boys and girls (at least 1 year after menarche). The overall adverse events in the simvastatin group were similar to those in the placebo group. Doses greater than 40 mg have not been studied in this population. In this limited controlled study, simvastatin was not found to have a significant effect on growth or sexual maturation in adolescent males or females, or on menstrual cycle length in adolescent females. (See Dosage and Administration; Adverse Reactions; Clinical Trials).

It is recommended that adolescent females use appropriate contraceptive methods during simvastatin treatment (see Contraindications; Precautions; Use in Pregnant and Lactating Women). Simvastatin has not been studied in patients younger than 10 years of age or in premenarchal girls.

Other fibrates:

When fibrates other than gemfibrozil are used in combination with simvastatin, the risk of myopathy is increased; the benefits and risks should be carefully weighed when used in combination.

Niacin (≥1 g per day): Cases of myopathy/rhabdomyolysis have been observed with concomitant use of simvastatin with lipid-modifying doses of niacin (≥1 g/day) (see PRECAUTIONS, Myopathy/Rhabdomyolysis).

Calcium channel blockers: The risk of myopathy/rhabdomyolysis may be increased when verapamil, diltiazem, or amlodipine are used concomitantly with simvastatin (see DOSAGE AND ADMINISTRATION; PRECAUTIONS; MYOPATHY/RHABOMYLOSIS).

Moderate CYP3A4 Inhibitors: Patients taking drugs listed in the instructions that have a moderate inhibitory effect on CYP3A4 may have an increased risk of myopathy when taking simvastatin in combination, especially at higher doses.

Amiodarone: The risk of myopathy/rhabdomyolysis may be increased when amiodarone is co-administered with simvastatin. (See PRECAUTIONS, Myopathy/Rhabdomyolysis)

Fusidic Acid: Concomitant use of fusidic acid may increase cases of myopathy/rhabdomyolysis. (See PRECAUTIONS, Myopathy/Rhabdomyolysis; Pharmacokinetics)